About Spectral Genomics
An independent biotechnology intelligence platform that tracks experimental drugs, analyzes clinical evidence, and estimates the probability of drug development and regulatory success.
Why we exist
Information about experimental drugs is scattered across trial registries, regulatory databases, scientific journals, and company filings. Each source tells part of the story, and very little of it explains what the evidence actually means. Spectral Genomics connects those sources into a single record for each drug and adds independent analysis on top.
Who it is for
- Scientists, researchers, and healthcare professionals who want to understand how a drug works, how strong the clinical evidence is, and how it compares with alternatives.
- Biotech investors and analysts who want to understand development risk, upcoming milestones, and how similar programs have fared historically.
Both audiences read the same underlying record. We keep scientific conclusions separate from development and investment perspectives.
What we cover
- Drug intelligence: individual drug profiles, mechanisms, indications, and development stages.
- Clinical intelligence: trial results, endpoints, safety findings, and historical success rates.
- Company intelligence: sponsor pipelines, milestones, and disclosures.
- Scientific knowledge: original explainers on drug development, regulatory science, and genomics.
Each drug profile shows historical approval odds for every development program: how often comparable programs at the same stage were eventually approved. They are labeled benchmarks, not predictions for individual drugs.
Our data
We build on public sources first: ClinicalTrials.gov, the FDA’s Drugs@FDA and openFDA databases, PubMed, SEC EDGAR, and the WHO International Clinical Trials Registry Platform. Every record links back to its source.
Our standards
Read our editorial standards for how we source, label, and correct content, and our disclaimer for the limits of what this site provides.